ストックスクリーナーアプリを入手
24.21
1.34%
0.32
アフターアワーズ：
23.99
-0.22
-0.91%
Aktis Oncology Inc (AKTS) 最新ニュース
AKTS|Akoustis Technologies Ord Shs|Price:24.170|Chg%:+0.280 - TradingKey
Has Aktis Oncology (AKTS) Fallen Far Enough To Be Below Fair Value? - simplywall.st
AKTIS ONCOLOGY INC : LEERINK PARTNERS ASSUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $33 - Bitget
Aktis Oncology Inc : Leerink Partners Assumes - Moomoo
Aktis Oncology director Ken Herrmann sells $119,274 in stock By Investing.com - Investing.com Australia
Form 4 Aktis Oncology Inc For: 21 July By Investing.com - Investing.com Nigeria
Aktis Oncology (AKTS) director sells 4,856 shares after exercising options - Stock Titan
Aktis Oncology director Ken Herrmann sells $119,274 in stock - Investing.com
Aktis Oncology director Ken Herrmann disposes of common shares worth $119,256.78 - Bitget
Aktis Oncology director Ken Herrmann disposes of 3,065 common shares worth $77,279.54 - Bitget
AKTS Pulls Back After Recent Gains: Key Levels to Watch for Aktis Oncology (AKTS)Volatility Skew - dars.gov.et
Aktis Oncology, Inc. (AKTS) director sells 3,065 post-exercise - Stock Titan
Akoustis Technologies (AKTS) insider plans 4,856-share stock sale after option exercise - Stock Titan
AKTS Options Chain — NASDAQ:AKTS - TradingView
Enterprise value to EBIT forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to revenue forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Form 144 AKTIS ONCOLOGY For: 17 July By Investing.com - Investing.com Nigeria
Aktis Oncology, Inc. SEC Filing (Jul 17, 2026) - Stock Titan
AKTS Options Volatility — NASDAQ:AKTS - TradingView
Price to sales forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
New Options Listings Include Aktis Oncology Inc (AKTS) - GuruFocus
AKTS Maintained by JP Morgan -- Price Target Raised to $33.00 - GuruFocus
J.P. Morgan Maintains Aktis Oncology(AKTS.US) With Buy Rating, Raises Target Price to $33 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
Price to book forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Price to earnings forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Enterprise value to EBITDA forward of Aktis Oncology, Inc. – NASDAQ:AKTS - TradingView
Aktis oncology CMO sells $1.39m in shares By Investing.com - Investing.com India
Aktis Oncology COO Ron-Bigger sells $1.39m in shares - Investing.com UK
Aktis Oncology Insider Sold Shares Worth $1,387,558, According to a Recent SEC Filing - Moomoo
Aktis Oncology COO Ron-Bigger sells $1.39m in shares By Investing.com - Investing.com Australia
Aktis oncology CMO sells $1.39m in shares - Investing.com
Form 4 Aktis Oncology Inc For: 10 July By Investing.com - Investing.com South Africa
Aktis Oncology Insider Sold Shares Worth $1,388,701, According to a Recent SEC Filing - Moomoo
Aktis Oncology Insiders Sold Shares Worth Over $2.8M - TradingView
Aktis Oncology (AKTS) COO exercises 50,000 options and sells matching shares - Stock Titan
Aktis Oncology (AKTS) CMO exercises 50,000 options, sells 50,000 shares in July 8 trades - Stock Titan
AKTS Q1 2026 Earnings: Wider-Than-Expected Loss Amid Pre-Revenue Pipeline Progress - dars.gov.et
Form 144 AKTIS ONCOLOGY For: 8 July By Investing.com - Investing.com Nigeria
[144] Aktis Oncology, Inc. SEC Filing - Stock Titan
Aktis Oncology (AKTS) Jefferies Global Healthcare Conference 2026 Summary - Quartr
Certain Options of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com
34,872,279 Common Stock of Aktis Oncology, Inc. are subject to a Lock-Up Agreement Ending on 8-JUL-2026. - marketscreener.com
DigitalOcean, Agios Pharmaceuticals, Kingsoft Cloud And Other Big Stocks Moving Higher On Tuesday - Benzinga
Aktis Oncology (AKTS) Gains 2.8% as Biotech Sentiment ImprovesVolume Breakout Ideas - dars.gov.et
Aktis is a strong buy at Raymond James on therapeutic platform - MSN
AKTS Q1 2026 Earnings: Results Miss Estimates as Pre-Revenue Biotech Continues Development - dars.gov.et
Aktis Oncology, Inc. Actuals & Estimates (NASDAQ:AKTS) - TradingView
AKTS Forecast — Price Target — Prediction for 2027 - TradingView
Aktis Oncology, Inc. News — NASDAQ:AKTS - TradingView
Aktis Oncology, Inc.(NasdaqGS: AKTS) added to S&P Global BMI Index - marketscreener.com
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):